S. Radhakrishnan, Wholetime Director of Cipla, speaks about the drugmaker’s acquisition of a 51 per cent stake in its South Africa partner Cipla Medpro, to strengthen its position in the fast-growing African drugs market. He further says that this has nothing to do with suspension of Medpro’s CEO Jerome Smith.
